Photo by Roger Pebody/AidsmapDolutegravir, a preferred HIV drug present in many combinations such as Dovato, Juluca and Triumeq, may cause unneeded blood clotting by activating the ‘blood clotting’ cells known as platelets. When platelets were exposed to dolutegravir at concentrations usually seen in people who use the drug, their clotting activity more than tripled, Renos Keniyopoullos told the 19th European AIDS Conference (EACS 2023) in Warsaw. These were ‘lab dish’ experiments and further clinical assessment in people living with HIV is warranted.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.